|
BioMarin Receives Orphan Drug Designation for Pompe Disease from the FDA
|
BioMarin |
|
Statement from IPA concerning Lumizyme Approval
|
IPA |
|
Genzyme Pompe Program Update - FDA Approves Lumizyme
|
Genzyme |
|
Pompe Program Update
|
Genzyme |
|
Extraordinary Measures Press Release
|
IPA |
|
IPA/Erasmus MC Pompe Patient Questionnaire - an Update
|
IPA |
|
Pompe Program Update
|
Genzyme |
|
Influenza Vaccinations and Pompe Disease
|
IPA |
|
Amicus Therapeutics Announces Plan to Initiate Phase 1 Study of AT2220 for Pompe Disease
|
Amicus |
|
IPA Feedback Survey: Response to Myozyme Supply Disruption
|
IPA |
